Azathioprine (AZA) is frequently used in patients with inflammatory bowel disease (IBD). However, toxic adverse reactions frequently develop and limit the clinical benefits. Currently, the precise mechanisms underlying thiopurine-related toxicity are not well understood.
Introduction
Azathioprine (AZA) is frequently used for steroid discontinuation and remission maintenance in patients with inflammatory bowel disease (IBD). However, toxic adverse reactions, including myelosuppression, frequently develop and limit the clinical benefits of this drug. The adverse reactions are divided into type A (those caused by the dose-dependent pharmacological activity of AZA/6-mercaptopurine (6-MP)) and type B (those involving allergic reactions and lacking dose dependency). The type A adverse reactions include myelosuppression (such as leukopenia and thrombocytopenia), alopecia, and increased susceptibility to infection and hepatitis, whereas type B reactions include fever, eruptions, arthralgia, myalgia, gastrointestinal symptoms (such as nausea), malaise and pancreatitis [1] . Currently, the precise mechanisms underlying thiopurine-related toxicity are not well understood. We aimed to elucidate thiopurine metabolism and its impact on patient toxicity.
Upon oral administration, AZA is absorbed into the plasma and is converted to 6-MP in a nonenzymatic reaction occurring within erythrocytes. Three major pathways then convert 6-MP into its various metabolites. The three critical enzymes corresponding to these pathways are xanthine oxidase (XO), thiopurine S-methyltransferase (TPMT), and hypoxanthine guanine phosphoribosyl transferase (HGPRT). The activity of TPMT is critically important in determining the balance between the production of 6-thioguanine nucleotide (6-TGN) and that of 6-methylmercaptopurine ribonucleotide . Individuals with lower TPMT activity display higher 6-TGN concentrations. Inosine triphosphate pyrophosphatase (ITPase) converts 6-thioinosine triphosphate (6-TITP) back to 6-thioinosine monophosphate (6-TIMP) so that 6-TITP does not accumulate. A deficiency in ITPase interrupts this cycle, leading to the accumulation 6-TITP (Fig 1) . We have previously reported that the inosine triphosphate pyrophosphatase (ITPA) gene mutation is closely related to adverse AZA/6-MP reactions in Japanese patients [2] . This prospective study was performed to investigate the relationship between the extent of thiopurine metabolism and adverse toxic reactions in thiopurine-naïve Japanese IBD patients. This study is the first investigation in which blood concentrations of 6-TGN have been continuously monitored over a long-term period in IBD patients being treated with AZA.
Materials and Methods Subjects
This study analyzed mutations in the TPMT and ITPA genes and the levels of specific metabolic products in IBD patients. From March 2008 to June 2011, we prospectively observed 50 Japanese IBD patients for 52 weeks who received AZA. Whole blood samples were drawn at 0, 1, and 2 weeks and then every 4 weeks. We analyzed the TPMT and ITPA gene mutations and measured the concentrations of 6-TGN after observation or after interruption due to adverse reactions. In Western countries, an AZA dosage of 2-3 mg/kg/day is recommended for the treatment of IBD patients [3] , but lower dosages (0.6-1.2 mg/kg/day) are used in Japanese individuals because of their relatively heightened sensitivities [4] . In this study, the initial AZA dosage was 1.0 mg/kg/day.
6-TGN
The 6-TGN levels in the red blood cells (RBCs) were measured using high-performance liquid chromatography (HPLC) as described by Lennard and Maddocks [6] with minor modifications [7] . The blood samples were placed in EDTA-2K tubes and stored at -20°C before further processing. Then, 500 μL of blood, 50 μL 100 mg/mL dithiothreitol, 50 μL 70% perchloric acid, and 500 μL dichloromethane were added to a new tube. After vortexing for 30 seconds, the tube was centrifuged for 15 minutes at 13,000 rpm, and then, 450 μL of the supernatant was transferred to another tube and hydrolyzed for 120 minutes at 105°C. The mixture was cooled to room temperature, and an additional centrifugation was performed for 3 minutes at 3,000 rpm. Next, 100 μL 2 M NaOH was added, and after vortexing for 30 seconds, the mixture was centrifuged for 5 minutes at 13,000 rpm. Then, 25 μL of the supernatant as analyzed at a flow rate of 500 μL/min on an Inertsil ODS-3 column (3.0 φ x 100 mm, 4 μm, GL Sciences, Tokyo, Japan) with an in-line filter (0.5-μm depth filter × 0.004 ID, Phenomenex, CA) at 50°C and a mobile phase of 40 mM KH 2 PO 4 and 7 mM sodium 1-octanesulfonate, which was adjusted to pH 3.5, to which methanol (98/2 v/v) was added. Absorbance was detected at 340 nm. HPLC Metabolism and transportation of AZA/6MP and its metabolites. XO, xanthine oxidase; TPMT, thiopurine S-methyltransferase; HGPRT, hypoxanthine-guanine phosphoribosyl transferase; ITPA, inosine triphosphate pyrophosphatase; IMPDH, inosine monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase; AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TUA, 6-thiouric acid; 6-MeMP, 6-methylmercaptopurine; 6-MeMPR, 6-methylmercaptopurine ribonucleotide; 6-TIMP, 6-thioinosine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TITP, 6-thioinosine triphosphate; 6-MeTIMP, 6-methylthioinosine monophosphate; 6-MeTITP, 6-methylthioinosine triphosphate; 6-TXMP, 6-thioxanthosine 5'-monophosphate; 6-TGN, 6-thioguanine nucleotide; 6-MeTGN, 6-methylthioguanine nucleotide.
doi:10.1371/journal.pone.0137798.g001
was performed using the LaChrom system (Hitachi, Tokyo, Japan). The inter-assay and intraassay coefficients of variation for 6-TGN in the blood were less than 6.2%.
Statistical analysis
In this study, leukopenia was defined as a white blood cell (WBC) count of 2500/μL or less. Hepatitis was defined as elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to over the upper limit of the normal range. For the analysis of adverse reactions, we considered the 6-TGN concentration at the time of diagnostic confirmation to be an adverse reaction, and for the analysis of the other factors, we also assessed the average 6-TGN concentrations from weeks 8 to 52 because these levels have been reported to remain largely consistent beyond week 4 [8] .
All statistical analyses were performed using IBM SPSS Statistics version 22.
Ethical considerations
These experiments were approved by the Ethics Committee of the Jikei University School of Medicine. We explained the purpose of the study and the methods involved to all participants prior to enrollment, and each individual provided their consent. Written informed consent was obtained from each participant after a full explanation of this study.
Results

Characteristics
Forty-eight of the 50 patients were observed for the complete duration of the study, and 2 patients dropped out. The characteristics of the patients are provided in Table 1 . In total, 48 patients with a mean age of 34.2, consisting of 29 males (60.4%) and 19 females (39.6%), were included; 29 patients had ulcerative colitis (UC) (60.4%), and 19 had Crohn's disease (CD) (39.6%).
TPMT, ITPA
All patients possessed wild-type TPMT gene sequences. The ITPA 94C>A mutation was detected in 19 patients (39.6%, all heterozygous, allele frequency: 19.8%). 
Adverse reactions
Adverse reactions developed in 14 of the 48 patients (29.2%), which involved some overlap, including leukopenia in 10 patients (20.8%), alopecia in 3 patients (6.3%), agranulocytosis in 1 patient (2.1%), hepatitis in 1 patient (2.1%), and rash in 1 patient (2.1%). One leukopenia patient developed agranulocytosis and alopecia. A total of six patients were discontinued AZA therapy due to adverse reactions ( Table 2 ). The mean age of these patients was 39.8, and there were 4 males (28.6%) and 10 females (71.4%); 10 had UC (71.4%), and 4 had CD (28.6%). Onset was reported to occur from 7 to 364 days after AZA administration.
Retrospective evaluations
The comparisons of adverse reactions are presented in Table 3 . The percentage of women in the adverse reactions group was higher than that in the group without adverse reactions (P < 0.02). Ten out of 19 women (52.6%) reported some adverse reactions. The comparison involving leukopenia is presented in Table 4 . In the leukopenia group, the percentages of woman and the rate of ITPA 94C>A mutation were higher than those in the without-leukopenia group (P < 0.05). Seven out of 19 women (36.8%) in addition to 7 out of 19 of patients with 94C>A (36.8%) had leukopenia. Three of the 14 patients (21.4%) whose average 6-TGN concentrations were over 450 pmol/8×10 8 RBCs had leukopenia, and 7 of the 34 patients (20.6%) whose average 6-TGN concentrations were less than 450 pmol/8×10 8 RBCs had leukopenia. There were no statistically significant differences between the groups with average 6-TGN concentrations of greater than and less than 450 pmol/8×10 8 RBCs from 8 to 52 weeks. The comparison of the patients with and without 94C>A is shown in Table 5 . The probability of leukopenia in the 94C>A group was higher than that in the group without 94C>A (36.8% vs. 10.3%, P < 0.05). 
6-TGN concentrations
The average concentrations of 6-TGN in the patients with 94C>A were generally higher than those in the patients without this mutation. However, there were no statistically significant differences between the groups (Fig 2A) . There were also no statistically significant differences between the groups based on adverse reactions, leukopenia, or gender ( Fig 2B, 2C and 2D) . Time points and 6-TGN concentrations in the presence of adverse reactions are shown in Table 2 . Only 4 out of 14 patients with adverse reactions exhibited high 6-TGN levels (28.6%), and only 3 out of 10 patients with leukopenia exhibited high 6-TGN levels (30.0%) (>450 pmol/8×10 8 RBCs, which is generally referred to as the toxic range [9] ). The onset of adverse reactions occurred within 52 weeks from the first week after administration. Three patients with leukopenia and two with alopecia possessed low 6-TGN levels immediately after the administration of AZA. We investigated the 6-TGN concentration changes leading to the onset of adverse reactions. Three patients with leukopenia exhibited low 6-TGN levels immediately after AZA administration. Patients with therapeutic 6-TGN levels (230-450 pmol/8×10 8 
Correlations between WBC and 6-TGN
We investigated the correlations between WBC counts and 6-TGN concentrations in all samples. No negative correlations were observed (r = -0.112, P < 0.01, n = 636) (Fig 3) .
Cumulative incidence of leukopenia
The Kaplan-Meier estimates of the cumulative incidence of leukopenia were higher for patients with the 94C>A mutation compared with those without the mutation (Fig 4) . 
Discussion
Previous studies indicated the main cause of AZA/6-MP-induced adverse reactions is a reduction in the activities of the metabolizing enzymes TPMT and ITPA. Influences of genetic polymorphisms on the activities of these metabolic enzymes have been reported. There are various TPMT activity-suppressing mutant alleles, and their expressions markedly vary among ethnicities. The major alleles are
(expressed in Chinese, Ghanaians, and Japanese), Ã 3D, Ã 4 (found in one northern European family), Ã 5, Ã 6 (expressed in Koreans), Ã 7 (expressed in Caucasian Europeans), and Ã 8
(expressed in African Americans), and alleles up to Ã 34 have been reported to date [5] . TPMT Ã 3C is the major mutation observed in Japanese individuals, and reports of other mutant genes are extremely rare. Japanese patients are typically heterozygous for this mutation (TPMT Ã 1/ Ã 3C), and it is present at a low frequency of 0.008-0.016 (0.8~1.6%) [10] [11] [12] . TPMT enzyme activity in individuals with the TPMT Ã 1/ Ã 3C genotype is approximately 25% lower than that in wild-type individuals [13] . The average concentration of 6-TGN in the group with 94C>A tended to be higher than that in the group without 94C>A. However, there was no statistically significant difference between the groups. b c d There were no statistically significant differences between the groups with and without adverse reactions (ARs) or the groups with and without leukopenia or between the males and females. doi:10.1371/journal.pone.0137798.g002
In addition several factors, such as ethnicity and drug interactions, play roles in TPMT activity. TPMT activity levels vary among ethnicities. Japanese patients have been reported to possess approximately 50% and 70% lower levels than those observed in Jewish and Caucasian Americans individuals, respectively [13, 14, 15] . According to previous reports, the concomitant use of aminosalicylic acids (ASAs), such as 5-ASA and sulfasalazine (SASP), results in significantly elevated 6-TGN levels and increases the incidence of adverse reactions, such as leukopenia [1, 16, 17] . Allopurinol potently inhibits XO, and a dose reduction to 25-33% of the standard daily dosage of AZA or of 6-MP is recommended when these two drugs are combined to prevent severe myelotoxicity [18] . In this study, all patients with leukopenia had been taking 5-ASA, and no patients took allopurinol.
Thiopurine-induced myelosuppression has been reported to occur dose-dependent [1] . Dubinsky et al noted leukopenic patients had higher 6-TGN levels [19] . A large number of reports have suggested that monitoring of erythrocyte 6-TGN concentrations may allow for adjustments in drug dose to reduce the incidence of thiopurine-induced adverse reactions in patients receiving these agents [8, 19] since Cuffari et al. reported the existence of a correlation between 6-TGN erythrocyte levels and the clinical efficacy of 6-MP [20] . However, a few reports have shown that leukopenia could be observed with variable 6-TGN levels [21] . Ohtsuka et al did not report any association between 6-TGN levels and haematological toxicity [22] . In the present study, the incidences of adverse reactions did not differ between the high- These results suggest that myelotoxicity may also occur at low 6-TGN levels, and the monitoring of 6-TGN concentrations is insufficient to predict adverse reactions. No negative correlation was noted between WBC counts and 6-TGN concentrations. Therefore, 6-TGN concentrations may not be associated with myelosuppression in Japanese IBD patients. Several studies have reported a correlation between TPMT activity/genotype and the risk of myelotoxicity [19, [23] [24] [25] [26] . However, we did not find an association between adverse reactions and the TPMT gene mutation in the present study. Takatsu et al. reported that the determination of the TPMT genotype may not be useful for predicting adverse reactions to AZA in Japanese IBD patients [27] . Ban et al. reported that TPMT mutations are not associated with myelosuppression in Japanese IBD patients [28] . In Japanese IBD patients, myelosuppression is not considered to be solely dependent upon TPMT activity, it is also associated with other factors.
Recent studies have shown that ITPA polymorphisms are significantly associated with flulike symptoms, rash, pancreatitis and leukopenia [29, 30] . ITPA enzyme activity in RBCs is reportedly absent in individuals who are homozygous for 94C>A, and levels are markedly lower (approximately 27% of the activity of the wild type) in those with heterozygous mutations [31, 32] . The allele frequency of the 94C>A polymorphism has been reported to be 31 out of 200 (0.155; 95% CI, 0.111-0.212) in 100 Japanese individuals [31] . This frequency is 2.6-fold higher than that reported in Caucasians (0.06) [32] , indicating that many more Japanese individuals may possess the ITPA mutation compared with the TPMT mutation. It is assumed that when ITPA activity is reduced or defective, toxic 6-TITP levels accumulate and induce adverse reactions. In Japanese individuals, the ITPA gene polymorphism may be more influential compared with the TPMT polymorphism in inducing thiopurine-induced myelosuppression.
This study is the first to continuously monitor blood concentrations of 6-TGN over a longterm period in IBD patients treated with AZA. Although no significant differences were observed, the average concentrations of 6-TGN in the patients with 94C>A were consistently higher than those in the patients without this mutation over the course of the study. Therefore, this mutation has some effects on 6-TGN levels in patients treated with thiopurines. Indeed, the incidence of leukopenia in the 19 patients with 94C>A was significantly higher than that in the 29 patients without 94C>A (P < 0.05). In addition, based on the Kaplan-Meier estimates, the cumulative incidence of leukopenia was higher for the patients with the 94C>A mutation compared with those without it. However, only 7 of the 19 patients (36.8%) with 94C>A developed leukopenia. Thus, this mutation does not ensure the development of adverse reactions to thiopurines, but it may represent a risk factor for leukopenia. Furthermore, factors other than increased serum levels of 6-TGN have been suggested to be involved in the onset of thiopurine-induced leukopenia in Japanese IBD patients. Further investigations are required, including the measurements of other metabolites of thiopurines, such as 6-TITP, and gene mutations in the transporter, which would affect the intracellular concentrations of important molecules, such as multidrug resistance-associated protein 4 (MRP4) [33] .
In conclusion, TPMT polymorphisms did not cause adverse AZA reactions in the Japanese subjects in this study. Seven out of 19 patients (36.8%) with the ITPA 94C>A mutation developed leukopenia; however, this mutation may not unequivocally increase the risk of developing adverse reactions to thiopurines. In addition, there are factors other than increased 6-TGN levels that are involved in the onset of leukopenia.
